OvaScience Inc. (NASDAQ:OVAS) shares shot up 3.4% during mid-day trading on Monday . The stock traded as high as $5.32 and last traded at $5.21, with a volume of 126,018 shares. The stock had previously closed at $5.04.

Several research firms have recently issued reports on OVAS. Oppenheimer Holdings Inc. restated a “hold” rating on shares of OvaScience in a research report on Monday, April 25th. Leerink Swann reaffirmed a “hold” rating and set a $7.00 price objective (up previously from $6.00) on shares of OvaScience in a research note on Sunday, May 8th. Finally, Credit Suisse Group AG reaffirmed a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $12.37.

The stock’s market cap is $143.20 million. The stock’s 50 day moving average is $5.34 and its 200-day moving average is $7.15.

OvaScience (NASDAQ:OVAS) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.08. The firm had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.14 million. During the same period in the previous year, the business earned ($0.65) EPS. The business’s quarterly revenue was up 630.0% on a year-over-year basis. On average, analysts forecast that OvaScience Inc. will post ($3.14) earnings per share for the current fiscal year.

In related news, CEO Michelle Dipp purchased 19,900 shares of the stock in a transaction dated Tuesday, May 10th. The stock was bought at an average cost of $7.72 per share, for a total transaction of $153,628.00. Following the completion of the acquisition, the chief executive officer now owns 971,921 shares of the company’s stock, valued at $7,503,230.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Richard Aldrich purchased 36,095 shares of the stock in a transaction dated Friday, May 13th. The shares were bought at an average price of $6.94 per share, with a total value of $250,499.30. Following the completion of the acquisition, the director now directly owns 604,185 shares of the company’s stock, valued at approximately $4,193,043.90. The disclosure for this purchase can be found here.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.